Maritide — full name maridebart cafraglutide, and known in its early trials as AMG 133 — is one of the most intriguing obesity drugs in development, because of *how* it works. It targets the same two hormone systems as tirzepatide, but it pushes one of them in the opposite direction. It is still investigational, but it already has real phase-1 human data.
In plain terms: it blocks one appetite receptor while switching on another — and, paradoxically, that combination takes weight off.
What it is
Maritide is not a simple peptide. It's a bispecific conjugate: a fully human monoclonal anti-GIPR antibody chemically joined to two GLP-1 analogue peptides by amino-acid linkers1. So it's a hybrid molecule — an antibody backbone carrying peptide agonists — engineered to hit two targets with one injection.
Its two jobs are opposites:
- Blocks the GIP receptor (GIPR) — it is a GIPR *antagonist*.
- Activates the GLP-1 receptor (GLP-1R) — the same appetite-suppressing target semaglutide uses.
That "block one, switch on the other" design is the whole story, and it's why maritide gets so much attention.
The mechanism — and the GIP paradox
Here's the puzzle. Tirzepatide is a blockbuster because it *activates* the GIP receptor (alongside GLP-1). Maritide does the reverse — it *blocks* GIPR — and it also produces weight loss. How can both agonizing and antagonizing the same receptor help?
This is known as the GIP paradox, and the leading resolution is elegant: sustained GIPR *agonism* may desensitize the receptor over time — effectively turning agonism into antagonism — an effect thought to be more pronounced in humans than in rodents3. In other words, the two strategies may converge on a similar end state at the receptor. It's genuinely unresolved science, and worth stating honestly: a 2026 review notes there is still **no clear evidence that GIPR agonism *or* antagonism alone drives appetite loss in humans** — the benefit shows up when GIP targeting is *combined* with GLP-14.
Where does the appetite effect actually happen? In the brain. Work in obese mice shows the conjugate needs both central GIPR and central GLP-1R signaling to deliver its full weight-loss effect, and it reaches appetite-regulating brain regions to switch on the relevant neurons2. So maritide is, at heart, a brain-appetite drug wearing a clever molecular design.
What the trials actually found
Maritide's evidence is early-stage but real — it has cleared the first human hurdle:
| Study | Model | Key result | Year |
|---|---|---|---|
| Véniant et al. — preclinical1 | Obese mice + monkeys | Reduced body weight and improved metabolic markers | 2024 |
| Véniant et al. — phase 11 | Adults with obesity (randomized, placebo-controlled) | Acceptable safety/tolerability and pronounced, dose-dependent weight loss | 2024 |
| Liu et al. — mechanism2 | Obese mice (CNS knockouts) | Full effect requires brain GIPR and GLP-1R signaling | 2025 |
The phase-1 result is the headline: in adults with obesity, maritide produced clear, dose-dependent weight loss with an acceptable early safety profile1. Its durability is the standout detail — in the multiple-dose cohorts, weight loss was maintained for up to about 150 days after dosing1. On the strength of that, maritide has advanced into larger trials; those later-stage results are what will decide whether the early promise holds.
In plain terms: the first human trial did what the design predicted — real weight loss, and it lasted unusually long between shots.
Why the long gaps between shots
That durability isn't an accident — it's the payoff of the antibody design. Antibodies clear from the body slowly, so a molecule built around one can keep working for weeks1. That's why maritide is being developed for infrequent injection — roughly monthly, potentially less — rather than the weekly rhythm of semaglutide and tirzepatide. For many people, fewer injections is a meaningful practical difference.
Side effects and safety
The honest position is that the safety picture is early. The phase-1 trial reported an *acceptable* safety and tolerability profile1 — but phase 1 is a small, short first look, not the years of data behind an approved drug. Because half of maritide's action is GLP-1 receptor agonism, the side effects most likely to matter are the familiar gastrointestinal ones of that class — nausea, vomiting, diarrhea — which tend to be dose-dependent and worst during dose escalation.
The honest caveats:
- It's phase-1-stage evidence. Rare and long-term risks are simply not characterized yet; that's what the larger ongoing trials are for.
- The GIP-antagonism biology is still debated. The paradox above isn't fully resolved, and the human role of GIP targeting alone remains unproven4.
- It's an injectable biologic conjugate, not a small peptide — its handling and risk context are those of a clinical drug.
Investigational status
To be plain: maritide is not an approved medicine. As of 2026 it is in active clinical development (Amgen's MariTide program), with phase-1 data published and larger trials underway. Everything solid that's known about it comes from those studies. This page explains what it is and what the trials showed — not how to use it — and it takes no position on sourcing.
The short version
Maritide (maridebart cafraglutide / AMG 133) is a bispecific conjugate that blocks the GIP receptor while activating the GLP-1 receptor — the mirror image of tirzepatide's GIP approach, yet it too drives weight loss (the GIP paradox)3. In a phase-1 trial it produced pronounced, dose-dependent weight loss that lasted up to ~150 days, supporting a monthly-ish dosing goal1. It is investigational, antibody-based, and brain-mediated — an educational overview only, not medical advice.